Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CNTB
CNTB logo

CNTB Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Connect Biopharma Holdings Ltd (CNTB) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
2.360
1 Day change
1.29%
52 Week Range
3.820
Analysis Updated At
2026/05/08
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

CNTB is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock lacks positive catalyst support, fundamentals are weak, technicals are bearish, and there are no proprietary buy signals. If you are impatient and unwilling to wait for a better entry, this is still not an attractive long-term entry today.

Technical Analysis

The trend is weak. MACD histogram is negative and expanding, which supports downside momentum. RSI_6 at 23.837 indicates the stock is deeply oversold rather than confirming strength, and converging moving averages suggest indecision rather than a confirmed reversal. Price at 2.36 is only slightly above S1 support at 2.337 and near S2 at 2.257, while still below the pivot at 2.467. That places the stock in a fragile area technically. Short-term pattern data also points to weakness, with an expected -2.88% move over the next week.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is mildly bullish on a relative basis because both the open interest put-call ratio and volume put-call ratio are below 1. However, absolute activity is low: today's option volume is only 37 contracts, and there is no strong evidence of a decisive directional bet. Implied volatility is extremely high at 253.35, which reflects a speculative name, while IV rank and percentile are low-to-moderate, so the options market is not showing a clear high-conviction accumulation signal.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
5

Positive Catalysts

  • There is no recent news in the past week, so there are no event-driven positive catalysts. The only mild positives are neutral hedge fund and insider positioning rather than active selling, and the options ratios lean slightly bullish. NULL of these are strong enough to justify a buy for a long-term beginner investor.

Neutral/Negative Catalysts

  • Technically, momentum is bearish and the stock is trading near support after a regular-session drop of 6.05%. No news, no congressional trading activity, no insider buying trend, and no significant hedge fund accumulation are present. The company also lacks valuation support in the data provided.

Financial Performance

Latest quarter: 2025/Q4. Revenue fell to 0, down 100.00% year over year, which is a major deterioration. Net income was -15,109,000, though that loss improved 69.65% YoY. EPS was -0.27, also improved 68.75% YoY but still negative. Gross margin was 100, but that is not meaningful in the context of zero revenue. Overall, the quarter shows no growth-based investment case.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data was provided, so there is no visible trend in analyst upgrades, downgrades, or target changes. Based on the available information, Wall Street pros would have little to no clear bullish case: there is no news catalyst, fundamentals are weak, and technicals are bearish. The main pro is that the stock is oversold and options ratios are not strongly bearish, but the cons dominate.

Wall Street analysts forecast CNTB stock price to rise
3 Analyst Rating
Wall Street analysts forecast CNTB stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.330
sliders
Low
7
Averages
8.67
High
10
Current: 2.330
sliders
Low
7
Averages
8.67
High
10
BTIG
Buy
initiated
$10
AI Analysis
2025-10-31
Reason
BTIG
Price Target
$10
AI Analysis
2025-10-31
initiated
Buy
Reason
BTIG initiated coverage of Connect Biopharma with a Buy rating and $10 price target. The firm believes rademikibart is "set up to thrive" in the acute settings of both indications of asthma and chronic obstructive pulmonary disorder, supported by its unusually fast and best-in-class onset of effect, the analyst tells investors.
Northland
Outperform
initiated
$7.50
2025-07-22
Reason
Northland
Price Target
$7.50
2025-07-22
initiated
Outperform
Reason
Northland initiated coverage of Connect Biopharma with an Outperform rating and $7.50 price target.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CNTB
Unlock Now

People Also Watch